Rapid Dose Therapeutics Corp(RDTCF)
$0.060.00 (0.00%)
RDTCF
Rapid Dose Therapeutics Corp financials statements
$0.06
At close:0.00 (0.00%)
Rapid Dose Therapeutics Corp (RDTCF) Ratios
0 Followers
Rapid Dose Therapeutics Corp Ratios
RDTCF's free cash flow for Q2 2027 was C$-10.31K. For the 2027 fiscal year, RDTCF's free cash flow was increased by C$0.00 and operating cash flow was C$-10.31K. See a summary of the company’s cash flow.
| Ratios | May 26 | May 25 | May 24 | Nov 22 | Feb 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.04 | 0.10 | 0.23 | 0.25 | 0.12 |
| Quick Ratio | 0.02 | 0.06 | 0.19 | 0.15 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.06 | 0.01 | 0.00 |
| Solvency Ratio | -0.28 | -0.75 | -0.73 | -2.74 | -1.69 |
| Operating Cash Flow Ratio | -0.03 | -0.17 | -0.79 | -1.22 | -0.87 |
| Short-Term Operating Cash Flow Coverage | -0.09 | -0.44 | -7.66 | -3.95 | -23.51 |
| Net Current Asset Value | C$ -10.09M | C$ -6.18M | C$ -4.36M | C$ -2.20M | C$ -4.02M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.62 | 1.60 | 1.30 | 0.47 | 0.29 |
| Debt-to-Equity Ratio | -0.74 | -0.50 | -0.78 | 5.69 | -8.28 |
| Debt-to-Capital Ratio | -2.87 | -1.01 | -3.48 | 0.85 | 1.14 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | -2.06 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.46 | -0.31 | -0.60 | 12.20 | -29.03 |
| Debt Service Coverage Ratio | -0.39 | -1.02 | -3.15 | -8.50 | -31.88 |
| Interest Coverage Ratio | -1.78 | 4.39 | -5.65 | -33.23 | -69.16 |
| Debt to Market Cap | 0.15 | 0.12 | 0.13 | 0.03 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.03 | 0.03 | 0.02 | 0.02 |
| Net Debt to EBITDA | -3.20 | -0.66 | -0.76 | -0.18 | -0.17 |
| Profitability Margins | |||||
| Gross Profit Margin | -34.50% | 56.59% | 55.24% | 76.77% | 36.79% |
| EBIT Margin | -78.29% | -200.07% | -357.35% | -476.83% | -7740.05% |
| EBITDA Margin | -59.78% | -188.53% | -296.57% | -433.11% | -7263.20% |
| Operating Profit Margin | -78.29% | 259.18% | -366.57% | -253.14% | -7394.23% |
| Pretax Profit Margin | -122.22% | -259.18% | -422.16% | -484.42% | -7847.45% |
| Net Profit Margin | -122.22% | -259.18% | -422.16% | -484.42% | -7847.45% |
| Continuous Operations Profit Margin | -122.22% | -259.18% | -422.16% | -484.42% | -7847.45% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 156.12% | -100.00% | 115.16% | 191.36% | 106.13% |
| Return on Assets (ROA) | -103.26% | -330.55% | -228.42% | -276.61% | -185.68% |
| Return on Equity (ROE) | 47.24% | 103.82% | 136.35% | -3373.73% | 5389.66% |
| Return on Capital Employed (ROCE) | 42.06% | -103.82% | 361.93% | -720.26% | -924.92% |
| Return on Invested Capital (ROIC) | 117.10% | -208.20% | 530.90% | -263.34% | -623.24% |
| Return on Tangible Assets | -103.26% | -330.55% | -228.42% | -276.61% | -185.68% |
| Earnings Yield | -17.00% | -25.52% | -23.44% | -32.57% | -30.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 16.48 | 6.89 | 4.65 | 9.59 | 0.92 |
| Payables Turnover | 0.80 | 0.47 | 0.41 | 0.30 | 0.04 |
| Inventory Turnover | 23.29 | 3.66 | 3.45 | 1.72 | 0.30 |
| Fixed Asset Turnover | 0.97 | 2.15 | 0.85 | 0.71 | 0.03 |
| Asset Turnover | 0.84 | 1.28 | 0.54 | 0.57 | 0.02 |
| Working Capital Turnover Ratio | -0.39 | -0.50 | -0.31 | -0.61 | -0.22 |
| Cash Conversion Cycle | -419.90 | -628.95 | -711.12 | -969.75 | -7243.42 |
| Days of Sales Outstanding | 22.15 | 52.97 | 78.48 | 38.08 | 398.48 |
| Days of Inventory Outstanding | 15.67 | 99.61 | 105.80 | 212.15 | 1196.92 |
| Days of Payables Outstanding | 457.72 | 781.53 | 895.40 | 1219.97 | 8838.82 |
| Operating Cycle | 37.82 | 152.58 | 184.28 | 250.23 | 1595.40 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.01 | -0.02 | -0.03 | -0.04 |
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.02 | -0.03 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | -301.78 | -199.79 | 0.00 | -74.33 | -2.48 |
| Capital Expenditure Coverage Ratio | -301.78 | -199.79 | 0.00 | -74.33 | -2.48 |
| Operating Cash Flow Coverage Ratio | -0.05 | -0.44 | -0.94 | -2.09 | -2.48 |
| Operating Cash Flow to Sales Ratio | -0.10 | -0.55 | -2.25 | -1.71 | -29.88 |
| Free Cash Flow Yield | -1.36% | -5.44% | -12.49% | -11.67% | -16.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.88 | -3.92 | -4.27 | -3.07 | -3.30 |
| Price-to-Sales (P/S) Ratio | 7.19 | 10.16 | 18.01 | 14.87 | 258.64 |
| Price-to-Book (P/B) Ratio | -2.78 | -4.07 | -5.82 | 103.58 | -177.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -73.51 | -18.37 | -8.00 | -8.57 | -6.17 |
| Price-to-Operating Cash Flow Ratio | -73.75 | -18.47 | -8.00 | -8.69 | -8.66 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | -0.67 | -0.38 | -0.01 | 0.07 |
| Enterprise Value Multiple | -15.23 | -6.05 | -6.83 | -3.62 | -3.73 |
| Enterprise Value | 25.25M | 23.77M | 20.66M | 27.45M | 27.47M |
| EV to EBITDA | -15.23 | -6.05 | -6.83 | -3.62 | -3.73 |
| EV to Sales | 9.11 | 11.40 | 20.26 | 15.67 | 270.66 |
| EV to Free Cash Flow | -93.08 | -20.62 | -9.00 | -9.03 | -6.45 |
| EV to Operating Cash Flow | -93.39 | -20.72 | -9.00 | -9.15 | -9.06 |
| Tangible Book Value Per Share | -0.05 | -0.04 | -0.03 | 0.00 | -0.00 |
| Shareholders’ Equity Per Share | -0.05 | -0.04 | -0.03 | 0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
| Revenue Per Share | 0.02 | 0.02 | 0.01 | 0.02 | 0.00 |
| Net Income Per Share | -0.03 | -0.04 | -0.04 | -0.08 | -0.10 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.56 | 1.30 | 1.18 | 1.02 | 1.01 |
| Research & Development to Revenue | 0.01 | 0.07 | 0.42 | 0.21 | 2.69 |
| SG&A to Revenue | 0.43 | 2.38 | 2.31 | 2.41 | 62.37 |
| Stock-Based Compensation to Revenue | 0.00 | 0.68 | 0.16 | 0.97 | 25.97 |
| Income Quality | 0.08 | 0.21 | 0.53 | 0.35 | 0.38 |
Currency in CAD
